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1267ﬁbrosis and, consequently, ventricular dysfunction.
Inhibition of collagen remodeling can lead to im-
proved cardiac function, demonstrating the relevance
of new insights into the compensatory remodeling
mechanism. Thus, our ﬁndings give new theoretical
support for the treatment of patients with ischemic
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a004978.Omega-3 Highly
Unsaturated Fatty Acids
and Arrhythmia Risk
Inﬂuences of Load Conditions and a
Differential Endogenous MetabolismWe read with great interest the recent report by
Nigam et al. (1) about the AFFORD (Multi-CenterStudy to Evaluate the Effect of n-3 Fatty Acids
[Omega-3] on Arrhythmia Recurrence in Atrial
Fibrillation) trial. Supplementation of 4 capsules ﬁsh
oil per day (containing a total of 1,600 mg eicosa-
pentaenoic acid, 20:5n-3, and 800 mg docosahexae-
noic acid [DHA], 22:6n-3) was shown not to reduce
recurrence of atrial ﬁbrillation. In parallel, markers of
inﬂammation or oxidative stress were not affected.
Up to now, numerous studies have provided a large
variety of potential effects attributed to highly un-
saturated fatty acid (HUFA) treatment ranging from
marked prognostic improvements in heart failure and
antiarrhythmogenic actions to no incremental effects.
Due to the divergent results, the question arises
whether mechanisms exist beyond an external HUFA
intake.
In heart failure, an inverse shift of serum fatty
acids occurs; particularly saturated and mono-
unsaturated fatty acids were increased, whereas
poly- and highly unsaturated omega-6 and omega-3
fatty acids were decreased (2,3). We have recently
shown that increased ventricular wall stress is
associated with reduced DHA levels (unpublished
data, P. Alter, January, 2015). Similar, but less
pronounced effects were found for eicosapentae-
noic acid and arachidonic acid (20:4n-6). Because
the liver is the major source of endogenous
HUFA, pseudocholinesterase activity, a marker of
hepatic metabolizing capacity, was examined
and shown to be inversely correlated with in-
creased end-diastolic and end-systolic ventricular
wall stress, which emphasizes the hypothesis of
a cardio-hepatic syndrome (e.g., inﬂuenced by
congestion). In addition, local variances of the
endogenous HUFA metabolism leading to in-
homogeneities of HUFA concentrations and effects
should be considered.
It was previously shown that systemic HUFA
levels in red blood cells and plasma correlate with
right atrial concentrations. Oral HUFA supplemen-
tation was incorporated into the atrial myocardium
(4). However, little is known about cardiac in-
ﬂuences on myocardial HUFA levels (5). We recently
found signiﬁcant differences of DHA concentrations
among atrial and ventricular myocardium in exper-
imental animals by using gas chromatography/mass
spectrometry (atrium 4.69  1.02% vs. ventricle
8.99  2.05%; p < 0.001) (unpublished, P. Alter,
January, 2015). It is suggested that different load
conditions, in particular increased wall stress, are
involved. Because DHA exhibits antiarrhythmogenic
actions, the question arises whether reduced
atrial DHA levels account for an increased risk of
atrial ﬁbrillation. Of note, intermediate DHA
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1268metabolism products, particularly tetracosapentae-
noic acid (24:5n-3) and tetracosahexaenoic acid
(24:6n-3), were increased in atrial, but not in ven-
tricular myocardium after intrapericardial HUFA
administration, which was associated with a higher
ventricular potential to ﬁnalize DHA synthesis.
Tetracosahexaenoic acid requires carnitine octanoyl-
transferase, a family member of carnitine acetyl-
transferases, for transportation into the endoplasmic
reticulum to undergo ﬁnal beta-oxidation. It was
previously shown that carnitine palmitoyltransferase
(1b and 2) is reduced in atrial compared with ven-
tricular myocardium. It is proposed to evaluate beta-
oxidation as a novel target for endogenous HUFA
concentrations. In accordance with the report by
Nigam et al. (1), no changes of HUFA levels were
found after a challenge with the proinﬂammatory
peroxisome proliferator-activated receptor-alpha
agonist fenoﬁbrate or in a talcum-induced pericar-
ditis model.
Up to now, involvement of cardiac load conditions
and the differential endogenous HUFA metabolism
were not sufﬁciently taken into account, which may
provide a rationale for divergent ﬁndings of HUFA
treatment in previous trials.Tobias Glück, MD
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Analysis to Data of
Previously Published
Chronic Heart Failure TrialsI enjoyed studying the contribution by Ahmad et al.
(1), and the accompanying editorial by Francis et al.
(2), published in the October 28, 2014 issue of the
Journal, about the application of cluster analysis to
the data from 1,619 participants of HF-ACTION (Heart
Failure: A Controlled Trial Investigating Outcomes of
Exercise Training) study. The investigators reported
that cluster analysis provided an advantage over
traditional phenotyping, based on the subjective
symptomatic assessment of the patients via the New
York Heart Association functional classiﬁcation I
to IV, and A to D stages, and imaging-based left
ventricular ejection fraction (LVEF) in predicting
outcomes (all-cause and cardiovascular, mortality,
and hospitalization risks) and response to surrogate
parameters (change in peak oxygen consumption and
in standard 6-min walk test). Clinicians following
longitudinally large numbers of heart failure (HF)
patients with a reduced LVEF in cardiology clinics
have long been accustomed to the incongruity be-
tween the functional classiﬁcation/staging (New York
Heart Association class II to IV) and LVEF (#35%) and
outcomes of their patients, stemming from our cur-
rent coarse phenotyping of a highly heterogeneous
disease as HF and the impact of comorbidities.
Ahmad et al. (1) arbitrarily employed 45 pre-
speciﬁed clinical variables and identiﬁed 4 pheno-
typic clusters, with intracluster similarities and
intercluster differences, in which they showed
diverse mortality and hospitalization rates. It is of
interest that in the exhaustive list of variables used
(1), a measure of the patients’ overall compliance with
their management in general, and with drug taking in
particular, is missing (issues of frequent concern in
cardiology clinics), for which the investigators are not
responsible. Ahmed et al. (1) and Francis et al. (2)
cited the reasons why a number of trials (refs. 7, 8,
and 35 in Ahmed et al. [1]) and patients with HF with a
reduced LVEF (refs. 5 to 8 in Francis et al. [2]) “have
failed to meet their endpoints” (2), and Ahmed et al.
(1) stated that “we have seen such little progress in
developing new treatments for this disorder.”
Although we need to adopt the philosophy of
enhanced and reﬁned phenotyping in designing
future HF clinical trials (2), what should have
